Expect Questions About Paxlovid or Molnupiravir for COVID-19

February 2022

You'll hear more about Paxlovid (nirmatrelvir/ritonavir), a new oral antiviral to treat COVID-19...and molnupiravir once it's approved.

Either will be an option for patients with mild to moderate COVID-19 who are at high risk of developing serious illness (age 65 or older, diabetes, etc)...regardless of vaccination status.

Be ready to handle these Rxs correctly...and ensure safe use.

Practical advice for a better career, with unlimited access to CE

Pharmacy Technician's Letter Canada includes:

12 issues every year, with brief articles about new meds and hot topics
120+ CE courses, including the popular CE-in-the-Letter
Helpful, in-depth Technician Tutorials
Access to the entire archive

Subscribe Today!

Already a subscriber? Log in

Volume pricing available. Get a quote

COVID-19 Expect Questions About Paxlovid or Molnupiravir for COVID-19
Practice Don't Let Your Pharmacy Fall Victim to Scams
IBS Think of Trulance as Similar to Constella or Ibsrela for IBS-C
Med Safety Improve Safety When Searching for Med Names
Contraceptives Listen for Concerns About Contraception and COVID-19 Infection
Pediatrics Promote Appropriate Use of Antibiotics for Ear Infections
Women's Health Help Sort Through Products to Track Ovulation and Fertility
Metformin Be Aware of Strategies to Help Patients Succeed With Metformin
GERD Keep Patients on PPIs for Treating GERD Safe

Expect Questions About Paxlovid or Molnupiravir for COVID-19

Practical advice for a better career, with unlimited access to CE

Table of Contents